To the best of our knowledge, it is the first time that the antifibrotic and anti-ELA effect of ACL inhibitors has been determined using the db/db mouse model and the feasibility of ACL as a therapeutic target for obesity-related CKD has been investigated. Here, ACLY is linked to obesity due to melanocortin 4 receptor deficiency.